Showing results (331-340 of 355) with videos related to

Sort By:
Pageof 36
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2015
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemiaRichard M Stone, Emanuele Mazzola, Donna Neuberg, et al.
Tissue Engineering. Part C, Methods|October 16, 2015
Functional Heart Valve Scaffolds Obtained by Complete Decellularization of Porcine Aortic Roots in a Novel Differential Pressure Gradient Perfusion SystemLeslie Neil Sierad, Eliza Laine Shaw, Alexander Bina, et al.
International Journal of Molecular Sciences|March 29, 2023
Landscape of <i>BCL2</i> Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with VenetoclaxLili Kotmayer, Tamás László, Gábor Mikala, et al.
Haematologica|April 2, 2026
First-year results of the International Leukemia/Lymphoma Target Board for pediatric relapsed and refractory hematological malignanciesUri Ilan, Judith M Boer, Maaike Luesink, et al.
Forensic Science International. Genetics|August 6, 2019
Evaluation of mitogenome sequence concordance, heteroplasmy detection, and haplogrouping in a worldwide lineage study using the Precision ID mtDNA Whole Genome PanelChristina Strobl, Jennifer Churchill Cihlar, Robert Lagacé, et al.
Lancet (London, England)|January 28, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrdan Verstovsek, Aaron T Gerds, Alessandro M Vannucchi, et al.
Lancet (London, England)|April 20, 2020
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trialJeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.
Blood|January 25, 2020
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuriaAlexander Röth, Jun-Ichi Nishimura, Zsolt Nagy, et al.
Cancers|February 15, 2022
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL StudyJosée M Zijlstra, George Follows, Rene-Olivier Casasnovas, et al.
Blood Advances|November 24, 2020
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosisAaron T Gerds, Michael R Savona, Bart L Scott, et al.
Pageof 36